SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response

SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response

As the SARS-CoV-2 pandemic continues to rage worldwide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and the reliability of commercially available high-throughput immunoassays. Our study demonstrates the administration of two doses o...

Full description

Saved in:
Bibliographic Details
Published in:Emerging microbes & infections Vol. 10; no. 1; pp. 2235 - 2243
Main Authors: Mileto, D., Fenizia, C., Cutrera, M., Gagliardi, G., Gigantiello, A., De Silvestri, A., Rizzo, A., Mancon, A., Bianchi, M., De Poli, F., Cuomo, M., Burgo, I., Longo, M., Rimoldi, S. G., Pagani, C., Grosso, S., Micheli, V., Rizzardini, G., Grande, R., Biasin, M., Gismondo, M. R., Lombardi, A.
Format: Journal Article
Language:English
Published: United States Taylor & Francis 01-01-2021
Taylor & Francis Group
Subjects:
Adult
Aged
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
BNT162 Vaccine - administration & dosage
BNT162 Vaccine - genetics
BNT162 Vaccine - immunology
COVID-19 - blood
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Emerging and Re-Emerging Coronaviruses
Female
Humans
Humoral response
Immunity, Cellular
Immunity, Humoral
Immunoassay
Longitudinal Studies
Male
Middle Aged
Prospective Studies
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
SARS-CoV-2 bnt162b2 mRNA vaccine
SARS-CoV-2 variants of concern
T-cell mediated respone
T-Lymphocytes - immunology
Vaccination
Young Adult
T-cell mediated respone
SARS-CoV-2 bnt162b2 mRNA vaccine
SARS-CoV-2 variants of concern
Humoral response
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As the SARS-CoV-2 pandemic continues to rage worldwide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and the reliability of commercially available high-throughput immunoassays. Our study demonstrates the administration of two doses of the BNT162b2 vaccine that elicited a robust SARS-CoV-2-specific immune response which was assessed up to 3 months after full vaccination in a cohort of 37 health care workers (HCWs). SARS-CoV-2-specific antibody response, evaluated by four commercially available chemiluminescence immunoassays (CLIA), was qualitatively consistent with the results provided by the gold-standard in vitro neutralization assay (NTA). However, we could not observe a correlation between the quantity of the antibody detected by CLIA assays and their neutralizing activity tested by NTA. Almost all subjects developed a SARS-CoV-2-specific T-cell response. Moreover, vaccinated HCWs developed a similar protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion. These results underline the importance of a solid vaccine-elicited immune response and a robust antibody titre. We believe that these relevant results should be taken into consideration in the definition of future vaccinal strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Supplemental data for this article can be accessed at https://doi.org/10.1080/22221751.2021.2004866
ISSN:2222-1751
2222-1751
DOI:10.1080/22221751.2021.2004866